Time and cost involved in measuring access to medicines: the case of Albania

被引：0
|
作者：
E. Petro [1 ]
I. R. Joosse [2 ]
A. C. M. Siebers [2 ]
T. Martopullo [2 ]
R. P. M. Hart [3 ]
A. K. Mantel-Teeuwisse [2 ]
H. A. van den Ham [2 ]
F. Suleman [2 ]
机构：
[1] Local Healthcare Unit,WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS)
[2] Utrecht University,WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, Discipline of Pharmaceutical Sciences, School of Health Sciences
[3] Lady of Good Counsel University,undefined
[4] University of KwaZulu-Natal,undefined
来源：
BMC Research Notes | / 18卷 / 1期
关键词：
Access to medicines; Cost expenditures; Data collection; Essential medicines; Monitoring tools; Research methodology; Albania;
D O I：
10.1186/s13104-025-07168-5
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Methylphenidate denied access to the WHO List of Essential Medicines for the second time
    Ribeiro, Johanne Pereira
    Lunde, Charlotte
    Gluud, Christian
    Simonsen, Erik
    Storebo, Ole Jakob
    BMJ EVIDENCE-BASED MEDICINE, 2023, 28 (02) : 75 - 77
  • [42] Evaluation of access to high-cost medicines in Australia using national claims data
    Lu, CY
    Williams, K
    Day, R
    VALUE IN HEALTH, 2005, 8 (06) : A28 - A28
  • [43] On Measuring the Cost of Children:The Case of Rural Maharashtra
    Indian Statistical Institute - Kolkata
    1600,
  • [44] Using health markets to improve access to medicines: three case studies
    Zubin Shroff
    Maryam Bigdeli
    Zaheer-Ud-Din Babar
    Anita Wagner
    Abdul Ghaffar
    David H Peters
    Journal of Pharmaceutical Policy and Practice, 9 (1)
  • [45] Secret safety warnings on medicines: A case study of information access requests
    Torka, Marc
    Mintzes, Barbara
    Bhasale, Alice
    Fabbri, Alice
    Perry, Lucy
    Lexchin, Joel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (04) : 551 - 555
  • [46] Time to entry of generic medicines in Malaysia: implications for pharmaceutical cost containment
    Fatokun, Omotayo
    Ibrahim, Mohamed Izham M.
    Hassali, Mohamed Azmi A.
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2013, 4 (04) : 203 - 210
  • [47] The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
    Tilson L.
    McGowan B.
    Bennett K.
    Barry M.
    The European Journal of Health Economics, 2004, 5 (4) : 341 - 344
  • [48] Measuring Success: Cost-Effectiveness and Expanding Access to Cochlear Implantation
    Saunders, James E.
    Francis, Howard W.
    Skarzynski, Piotr H.
    OTOLOGY & NEUROTOLOGY, 2016, 37 (02) : E135 - E140
  • [49] TIME TO MARKET ACCESS FOR ONCOLOGY MEDICINES IN GREECE: HAS IT CHANGED DURING THE CRISIS?
    Filosofou, S.
    Naoum, P.
    Kyriopoulos, D.
    Athanasakis, K.
    Theodorou, M.
    VALUE IN HEALTH, 2017, 20 (09) : A460 - A460
  • [50] Differences in time to patient access to innovative cancer medicines in six European countries
    Vancoppenolle, Julie M.
    Franzen, Nora
    Koole, Simone N.
    Retel, Valesca P.
    van Harten, Wim H.
    INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (05) : 886 - 894
12345